Study Overview: This research is testing a new drug called MRTX849, also known as adagrasib, for people with certain types of advanced cancer. The cancer must have a specific change in its genes called a KRAS G12C mutation. The goal is to see if the drug is safe and how well it works.
What does the study involve? Adagrasib is taken by mouth in pill form. The study will look at how the drug behaves in the body, what happens to it over time (pharmacokinetics), and its effects on the body (pharmacodynamics). Researchers will also check for any side effects and see if the cancer responds to the treatment.
Who can join? You can participate if you have a confirmed diagnosis of a solid tumor with the KRAS G12C mutation and if other standard treatments are not an option. You must have good organ function and no other active cancers.
- Study Length: Phase 1/2, early-stage study, specific duration not mentioned.
- Visits Needed: Regular check-ups and monitoring required.
- Risks: Possible side effects from the medication.